Ideal Cures unveil new technology to prolong drug release

Top Stories

»	Rupee slips to another low ahead of US Fed meeting
»	'Global concerns weighing heavily on Indian exports'
»	India to expand electronics manufacturing base to $400-bn
»	No need to worry at the US Bill restricting visas: Nasscom
»	India Kenya's largest Asian trading partner

SME Times News Bureau | 23 Jul, 2012
Ideal Cures, a leading player based here in film coating material for tablets, pellets and granules of pharma, health and dietary supplement companies, has developed an extended delivery system for tablets used for all classes of drug.

Extended release drug delivery system allows the release of any drug for a longer period of time with continuous availability of medication to patient or user, and thereby cuts the frequency at which such doses have to be administered.

Technically named instamodel blends, some of the extended release formulations developed using this technology are paracetemol, metformin hcl, diclofenac sodium, trimetazidine, gliclazide, metoprolol and carbamazepine.

"Instamodel blends open a new window for mid-sized pharma companies worldwide who look to longer shelf-life for products, while also offering more convenient treatment option to patients in the shortest time-frame," says Ideal Cures president Ashok Omray.

This, according to him, has been made possible by developing the perfect technology that is able to combine expients -- that that are the carriers of a drug to ensure absorption by the body -- with polymers so that the devivery of medication is as desired.

Suresh Pareek, another main inventor of the technology along with Omray, said Instamodel blends offer tomorrow's technology today and qualify for Gras or generally recognised as safe status with no reported incompatibility with the chosen drug substances.

"We are proud to say this is the first time that such a fast, result oriented product has been developed that is completely reliable, reproduceable and at par with all the regulatory requirements in terms of quality, consistency and stability," Pareek added.

The two inventors also highlighted the glals that Instamodel system offers phara firms: Almost nil time for developing formulations, quich launch to beat competition, cost effectiveness, simple technology and compliance to multiple pharma industry standards.

"Due to strong generic competition, many of the mid-sized pharma companies will have to evolve their portfolio by adapting themselves to controlled release systems of their older products," said Pareek, who is also the managing director of Ideal Cures.

"Processes may require longer time in the formulation development stage. But with the use of instamodel systems, phenomenal success can be achieved in the shortest possible time," added Pareek.

Headquartered in Mumbai, Ideal Cures has a presence in some 40 countries. It also has a subsidiary in Europe and three plants at Vasai, near Mumbai, Jammu in Jammu and Kashmir and Khambhat in Gujarat. It also has two research centres in Vasai and Mumbai.

Recently, the firm had secured a US patent for an innovation in film coating composition that is bot only cost-effective, but also gives an alternative to organic solvents like isopropyl alcohol and methylene chloride, toxic to environment and coating operators.